sooner rather than later. $4m cash at end of Dec 2023. $1.4 M R&D spend for that Dec quarter which was before recruitment for next stage including Korea started, trial costs are only going one way and that’s up.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-14
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
-0.001(0.83%) |
Mkt cap ! $16.43M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 6.1¢ | 5.9¢ | $4.649K | 77.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1240 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 106202 | 1 |
View Market Depth
| Last trade - 10.26am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.9¢ |
Change
-0.001 ( 3.28 %) |
||||
| Open | High | Low | Volume | ||
| 6.0¢ | 6.0¢ | 5.9¢ | 52400 | ||
| Last updated 10.26am 17/05/2024 ? | |||||
| ATX (ASX) Chart |